They saved my Dad’s life and I figured out what to do with mine
St. Joseph’s Healthcare Hamilton auto-immune disease study reduces risk of life-threatening infection
Story featured on:
- The Hamilton Spectator, Welland Tribune, St. Catharine's Standard
- Hamilton Community News
- CBC Hamilton
- CHCH Morning Live News
- Canadian Fire Fighter (cdnfirefighter.com)
- ArabNews24.ca
At 54, Tom Salisbury was a firefighter who developed joint pain and a cold that he couldn’t shake. When he began coughing up blood, his wife and daughters prepared for bad news. With the help of doctors at St. Joseph’s Healthcare Hamilton, Tom was diagnosed with a type of vasculitis, a rare auto-immune disease that causes inflammation of the blood vessels that can lead to hemorrhaging in the lungs and rapidly progressive kidney failure. Without treatment it is almost certainly fatal. Little did they know that having this illness would introduce them to a research study that potentially saved Tom’s life and altered the career path of his daughter.
Tom was admitted to hospital the weekend he was diagnosed and was given a course of immunosuppressants, including prednisone steroids. Steroids help treat vasculitis by suppressing the immune system to reduce inflammation, but they also put patients at a higher risk of developing life-threatening infections. On Monday morning, Tom was introduced to Dr. Michael Walsh who asked him to be a part of an international research study to improve outcomes for patients with vasculitis. During Tom’s treatment at St. Joe’s, his daughter Maddie Salisbury was at his side as much as she could while studying kinesiology.
“Patients that participate in research studies are people first; they’re not guinea pigs,” says Maddie Salisbury, Tom’s 26-year-old daughter. “I was so captivated by the type of life-changing research going on at St. Joe’s, I jumped at the chance to work with Dr. Walsh on studies like the one that helped save my dad’s life.”
“Infection is the most common cause of death associated with this kind of vasculitis disease, with one in three patients ending up in the hospital with a serious infection within their first year of treatment,” says Dr. Michael Walsh, Researcher at St. Joseph’s Healthcare Hamilton and Associate Professor, McMaster University. “Our study found that lower doses of steroids are as effective as higher doses in controlling the disease, while at the same time significantly reducing the risk of serious infections for patients.”
Prior to Dr. Walsh’s study, there were very little guidelines for the amount of steroids to prescribe during vasculitis treatment. Tom Salisbury was fortunate not to develop a serious infection during his treatment, something more patients will be able to avoid because of the results of PEXIVAS study.
With these findings, clinicians around the world have already begun to revise their standards for steroid treatment of vasculitis, therefore reducing the risks of serious infections. Findings from this clinical trial, called PEXIVAS (Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody [ANCA]-Associated Vasculitis) will appear in the New England Journal of Medicine on February 13, 2020.
St. Joseph’s Healthcare Hamilton, a proud member of St. Joseph’s Health System, is a teaching hospital affiliated with the world-renowned McMaster University.